Akari Therapeutics, Plc — Company profile
Healthcare · Biotechnology · United States
Last price 8.24 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 18.83M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Details
| Name | Akari Therapeutics, Plc |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 6 |
| Ceo | Abizer Gaslightwala |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US00972G4055 |
| Cusip | 00972G405 |
| Cik | 0001541157 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Abizer Gaslightwala | Chief Executive Officer, President and Director |
| Kameel D. Farag | Interim Chief Financial Officer |
| Dr. Satyajit Mitra Ph.D. | Executive Director and Head of Oncology |
Contact
| Address | 401 East Jackson Street, Suite 3300, Tampa, Florida 33602, United States |
| Phone | 929 274 7510 |
| Website | https://www.akaritx.com |